The Liver Meeting

The Liver Meeting

Source:

Lawitz E, et al. Poster 1693. Presented at: American Association for the Study of Liver Diseases: The Liver Meeting Digital Experience; Nov. 13-16, 2020.

Disclosures: Lawitz reports no relevant financial disclosures.
January 29, 2021
1 min watch
Save

VIDEO: DUR-928 well tolerated at three doses for treatment of NASH

Source:

Lawitz E, et al. Poster 1693. Presented at: American Association for the Study of Liver Diseases: The Liver Meeting Digital Experience; Nov. 13-16, 2020.

Disclosures: Lawitz reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Eric Lawitz, MD, from the Texas Liver Institute, University of Texas Health, San Antonio, spoke about DUR-928, a daily oral treatment for nonalcoholic steatohepatitis.

DUR-928 was well tolerated at 50 mg, 150 mg and 300 mg, with no serious adverse events reported, according to Lawitz. At 4 weeks, the median liver fat reduction was –18% at 50 mg, –19% at 150 mg and –23 at 300 mg as measured by MRI-PDFF.

Lawitz said that DUR-928 showed overall improvement in multiple markers such as liver enzymes, liver imaging and serum lipid profiles.